• Publications
  • Influence
Improved survival in steroid‐refractory acute graft versus host disease after non‐myeloablative allogeneic transplantation using a daclizumab‐based strategy with comprehensive infection prophylaxis
Approximately 15% of patients undergoing non‐myeloablative allogeneic haematopoietical cell transplantation (NMHCT) develop steroid‐refractory acute‐graft versus host disease (aGVHD), a usually fatalExpand
  • 75
  • 6
Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis, venous thrombosis, and bone marrow failure. Seventeen patients with debilitating PNH, including 8 who wereExpand
  • 14
  • 2
Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation.
We studied bone mineral density (BMD) in 79 long-term survivors of allogeneic stem cell transplantation (SCT) (median follow-up: 78 months; range: 38-160). Seventy patients received a total bodyExpand
  • 58
Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL
Abstract 4296 The proteosome inhibitor bortezomib (bort) augments NK cell TRAIL and perforin/granzyme-mediated caspase-8 activity in tumor cells. We have observed that bort sensitizes human tumorsExpand
  • 7
The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.
The advent of imatinib, and subsequently, other tyrosine kinase inhibitors (TKIs) has relegated allogeneic stem cell transplantation (SCT) to second-or third-line therapy for chronic phase-chronicExpand
  • 7
Long-term persistence of nonpathogenic clonal chromosome abnormalities in donor hematopoietic cells after allogeneic stem cell transplantation.
We describe the cases of two unrelated patients who exhibited multiple chromosomal abnormalities in donor cells after allogeneic peripheral blood stem cell transplantation (PBSCT). The patients wereExpand
  • 4
Chronic GVHD manifesting as parotitis after allogeneic hematopoietic SCT
Graft-versus-host disease (GVHD) is artificially divided into acute and chronic forms depending on its date of onset. Although there may be a continuum of clinical findings, chronic GVHD can affectExpand
  • 3
Adoptive Infusion of Ex Vivo Expanded Autologous Natural Killer (NK) Cells in Cancer Patients Treated with Bortezomib to Sensitize to NK-TRAIL Cytotoxicity.
Abstract 4080 Poster Board III-1015 Ligation of inhibitory receptors renders natural killer (NK) cells inactive against autologous tumors. Recently, bortezomib (bort) was shown to sensitize a varietyExpand
  • 2
A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity
Abstract 1001 The proteosome inhibitor bortezomib sensitizes tumors in-vitro and in-vivo to autologous NK cell killing by augmenting NK cell TRAIL and perforin/granzyme-mediated caspase-8 activityExpand
  • 3
Rapid donor T‐cell engraftment increases the risk of chronic graft‐versus‐host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure
The risk of graft‐rejection after allogeneic hematopoietic cell transplantation using conventional cyclophosphamide‐based conditioning is increased in patients with bone marrow failure syndromesExpand
  • 3